Notice of Correction Regarding Research Using Control Subjects for NIDDK PAR-13-028 "Research Using Subjects From Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3)"


Notice Number: NOT-DK-13-006


Key Dates

Release Date:  February 11, 2013

Related Notices

PAR-13-028

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

This Notice clarifies that PAR-13-028  "Research Using Subjects from Selected Type 1 Diabetes Clinical Studies (Living Biobank) (DP3)" can fund studies that require the recruitment of control subjects (including healthy controls, for example) as part of a larger study of subjects enrolled and followed in Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC).  Healthy controls are also allowed in TrialNet, since the Pathway to Prevention already recruits and follows healthy control subjects.  The following sections of the FOA are amended, with amendments shown in bold:

Section I. Funding Opportunity Description

This opportunity is intended to fund projects using subjects who have been phenotypically and genetically characterized for risk of developing type 1 diabetes through the Type 1 Diabetes TrialNet Pathway To Prevention clinical research network, and projects using subjects currently enrolled and followed for diabetic complications in the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC). A small number of additional controls (for example, healthy controls) may be recruited if well justified.

This FOA provides a means of accessing this unique population being followed in DCCT/EDIC, and a small number of newly-recruited controls (if required)

Applicants may propose to perform tests on subjects and/or collect samples "on demand" at regularly scheduled EDIC study visits, or scheduled as needed in the case of required newly recruited controls

Section IV. Application and Submission Information

2. Content and Form of Application Submission

Research Strategy

All other aspects of the FOA remain unchanged.

Inquiries

For TrialNet:

Lisa M. Spain, Ph. D.
Program Director for Immunobiology of Autoimmune Endocrine Diseases
Division of Diabetes, Endocrinology, and Metabolism
National Institute of Diabetes Digestive & Kidney Diseases (NIDDK)
Telephone: 301-451-9871
Email:spainl@niddk.nih.gov

For DCCT/EDIC:

Catherine C. Cowie, PhD, MPH 
Senior Advisor & Director for Diabetes Epidemiology
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone:  301-594-8804
Email:  cowie@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy
NIH . . . Turning Discovery Into Health

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.